Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
DUSP22 CRISPR/Cas9 KO Plasmid (h): sc-405867
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- DUSP22 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the DUSP22 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: DUSP22 Antibody (9J2): sc-135602
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DUSP22 CRISPR/Cas9 KO Plasmid (h) | sc-405867 | 20 µg | $397.00 |
Overview
DUSP22 encodes a dual-specificity phosphatase that dephosphorylates serine/threonine and tyrosine residues to modulate kinase-driven signaling networks. It is implicated in regulation of MAPK pathway outputs and phospho-dependent control of immune receptor signaling, influencing transcriptional programs, cell activation states, and apoptosis. By tuning phosphorylation dynamics, DUSP22 contributes to cellular homeostasis in hematopoietic and other tissues where stimulus-responsive signaling is critical. Altered DUSP22 expression or pathway context has been linked to dysregulated immune signaling and oncogenic processes, supporting its use as a mechanistic node in studies of signaling-driven disease biology.
DUSP22 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the DUSP22 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the DUSP22 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the DUSP22 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish DUSP22 protein expression.
This CRISPR knockout system enables efficient generation of DUSP22-deficient cell models for investigation of DUSP22 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting DUSP22 exon(s) critical for DUSP22 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple DUSP22 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by DUSP22 CRISPR/Cas9 KO Plasmid (h) and DUSP22 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the DUSP22 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by DUSP22 HDR Plasmid (h) and DUSP22 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by DUSP22 homology arms to support homology-directed repair at defined DUSP22 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.